Clinical trial
Prospective Observational Study on the Clinical Efficacy of Teclistamab and Talquetamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium
NCT06477783 is registered in ClinicalTrials.gov with Universitaire Ziekenhuizen KU Leuven as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Observational Study on the Clinical Efficacy of Teclistamab and Talquetamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- December 1, 2024
- Completion date
- September 30, 2027
- Enrollment
- 100 (estimated)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.